Navigation Links
The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo

Current Board and Management's History of Over-Promising & Under-Delivering Bodes Ill for Shareholder Value Going Forward

CINCINNATI, March 6 /PRNewswire-FirstCall/ -- The LCA-Vision Full Value Committee announced today that it has released the following letter to the stockholders of LCA-Vision, Inc.:

March 6, 2009

Dear Fellow Shareholder:

As one of the largest shareholders at LCAV, with over 11% of the stock, we believe that the stockholders' investment in LCAV has reached a crisis point. In the face of one of the worst recessions in recent history, with no end clearly in sight, we are saddled with a Board and management team with a history of over-promising and under-delivering. While they express confidence in their plans and strategies, based on our experience in building LCAV into the pre-eminent laser vision company and successfully weathering the last recession, unfortunately we do not at all share that confidence.

As stockholders with a significant amount of money at stake and the benefit of a long memory and deep operational knowledge of the business, we urge stockholders not to fall victim to the hollow promises you are hearing, yet again, from the Board and management team. To protect the remaining value of your investment, we strongly urge you to vote the WHITE proxy card to remove the current members of the Board and to elect the Full Value Committee's highly qualified, experienced nominees. If elected, our nominees will restore the management team that helped build LCAV into one of the fastest growing small cap companies in the United States, according to both Fortune magazine and Business Week.

Perhaps you do not share our concerns about LCAV's viability under the current Board and management in the current economic climate. You may take comfort from their track record, as they would like to portray it. We certainly do not.


  • You are satisfied with the Company's loss of approximately 90% of stockholder value, you should vote to keep the current Board and management team.
  • You are satisfied with losing national market share while at the same time much of your money has been spent to open 19 more vision centers, you should vote to keep the current Board and management team.
  • You are satisfied with the Board continuing to significantly dilute shareholders with generous equity awards to themselves and the management team, including approximately 2% of the outstanding shares in a single grant just last Monday that we believe may have been a violation of the caps in the Company's own stock incentive plans, you should vote to keep the current Board and management team.
  • You are satisfied with the Company's same store procedure volume lagging the industry as it has done for the last seven quarters, you should vote to keep the current Board and management team.
  • You are satisfied with the Company continuing to rapidly burn through its remaining cash reserves, which it appears they will do far more rapidly than they have told you, you should vote to keep the current Board and management team.
  • You are comfortable with the Company diversifying into new business lines with questionable revenues and uncertain margins while at the same time the core LASIK business is hemorrhaging $2.5 million of cash per month, you should vote to keep the current Board and management team.
  • You want to suffer the same fate as the stockholders of MSO Medical (Mr. Straus's last venture) which filed for bankruptcy, you should vote to keep the current Board and management team.
  • You are comfortable with the Company continuing to promise you a rosy future while yet again justifying its subpar performance, you should vote to keep the current Board and management team.

You may have seen that a proxy advisory firm recently recommended that shareholders not replace the current Board at this time. Naturally, we are disappointed that this firm -- which does not have any in-depth knowledge of LCAV or the laser correction industry and is not an LCAV investor -- took this position. You should know, however, that their support of the current Board was tepid, at best, acknowledging the Company's decline under Steve Straus's management, as well as expressing concerns regarding Board compensation and the poison pill that the Board adopted without shareholder approval, among other issues.

If on the other hand, you're ready for a change, the time is now.

Under Mr. Straus and the Board, LCAV has missed consensus estimates every single quarter of 2008 and six of the eight quarters that Mr. Straus has served as CEO. Needless to say, the unbroken record of over-promising and under-delivering has severely damaged the value of all of our LCAV investments. Although they acknowledge there were some mishaps in the past, the Board and Mr. Straus would now like you to believe that business has "stabilized," implying that LCAV will be able to achieve 2008 procedural volume levels in 2009, a prospect we find highly unrealistic.

In addition, they have told you that LCAV has a three-year cash position at the 90,000 annual procedural level. Yet, deep within a filing with the Securities and Exchange Commission, they recently acknowledged for the first time that the Company now expects that the first quarter 2009 procedural volume will be down "about 35%" from the first quarter of 2008, seriously jeopardizing their own prediction of a three-year cash position.

What else is the Company not telling stockholders? As you decide how to vote your shares, consider the following concerns, which are based on our intimate understanding of the business and the industry:

  • We believe the Company's first quarter 2009 procedure volume will decline well in excess of the 35% projected by management, compared to the first quarter 2008.
  • We believe the Company's new marketing initiatives are NOT working. In fact, we believe the Company may report one of its highest marketing costs per procedure in the first quarter 2009, ever, possibly even exceeding $500.
  • We believe that for the first time in over a decade, LCAV will likely report a significant adjusted loss in the first quarter 2009, seasonally the Company's strongest and most profitable quarter. If so, this does not bode well for the rest of the year and management's latest set of promises.

Everything we have heard from the current Board and management demonstrates that they lack a fundamental understanding of LCAV's business and the core drivers of the Company's profitability. They lack an understanding of the major problems confronting our Company, and have minimal insight into how to fix them. As they make vapid promises of future performance, they are asking stockholders for more time and patience.

But for stockholders, there can be no more time, there can be no more patience. In the race between the cash running out and the key physician and employee asset base crumbling, on the one hand, and the Board and management scrambling to learn the business, on the other, the stockholders stand to be the ultimate losers.

Time is of the essence. Please sign, date and return your WHITE consent card as soon as possible with a vote to remove the existing members of the Board and to replace them with our highly qualified nominees. As the Company's largest shareholders, with unique insights and unparalleled industry and Company-specific knowledge, we can tell you the status quo is NOT working. We believe the Company's very existence as a going concern may soon be in question unless stockholders act NOW.

SOURCE The LCA-Vision Full Value Committee
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Leading Proxy Advisory Firm RiskMetrics Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
2. LCA-Vision to Present at the Raymond James 30th Annual Institutional Investors Conference
3. Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group
4. The LCA-Vision Full Value Committee Files Detailed Presentations
5. LCA-Vision Reports Tangible Results from Business Strategy
6. LCA-Vision Announces Appointment of Edgar F. Heizer to Board of Directors
7. LCA-Vision Announces Consent Solicitation Deadline; Urges Stockholders to Return Gold Consent Revocation Card
8. LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results
9. LCA-Visions National Lasik Network Named as U.S. Provider for National Vision Administrators
10. The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders
11. LCA-Vision to Hold Corporate Update Conference Call and Q&A Session on February 6
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... choice for innovative, patient centered orthopedic care. Led by John Vitolo, M.D., ... injury or chronic condition, the team at Advocare Orthopedic & Sports Medicine is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in ... can visit Dr. Margulies to experience the best available orthodontic experience in the area. ... "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the ...
(Date:11/30/2015)... ... 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene ... of Dental Medicine in 1935. His father graduated from NYU School of Dentistry ... as well as their commitment and passion to the Practice of Dentistry. Continuing ...
(Date:11/30/2015)... ALEXANDRIA, VA (PRWEB) , ... November 30, 2015 ... ... American Association of Poison Control Centers’ National Poison Data System (NPDS) reveals that ... centers managed almost 3 million cases, over two million of which were human ...
(Date:11/30/2015)... ... November 30, 2015 , ... Two years ago, Debbie Gregory, the ... David Lynch Foundation, learning Transcendental Meditation (TM). After encouraging a number of veterans ... so that she could talk the talk. , TM is becoming one of the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... LAKE CITY , Nov. 30, 2015 Booth ... (NYSE: VAR ) will exhibit a broader array of ... of the Radiological Society of North America ... Varian exhibit at the meeting will feature X-ray components "At ... CT tube, a line of products from Varian,s Claymount brand, ...
(Date:11/30/2015)... Belgium , Nov. 30, 2015   VolitionRx Limited ... developing blood-based diagnostic tests for a broad range of cancer ... at the LD Micro Conference, which will be held December ... Attending from VolitionRx will be David Kratochvil , ... Vice President of Investor Relations. ® blood-based ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. ... pharmaceutical company focused on acquiring and developing innovative therapies ... the appointment of Keith A. Katkin as ... Gregory J. Flesher , chief executive officer for OticPharma, ... successful organizations.  As chairman, he will be able to ...
Breaking Medicine Technology: